CG Oncology (CGON) Operating Expenses (2023 - 2026)

CG Oncology (CGON) has 4 years of Operating Expenses data on file, last reported at $67.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 59.67% year-over-year to $67.5 million; the trailing twelve-month figure through Mar 2026 stood at $220.0 million (up 62.91% YoY), and the FY2025 full-year result was $194.8 million, up 68.23% from the prior year.
• Operating Expenses for Q1 2026 stood at $67.5 million, up from $51.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $67.5 million in Q1 2026 and bottomed at $9.9 million in Q1 2023.
• The 4-year median for Operating Expenses is $28.3 million (2024), against an average of $33.4 million.
• The widest annual swing landed in 2024, when Operating Expenses surged 131.95%; it then soared 32.51% in 2025.
• A 4-year view of Operating Expenses shows it stood at $19.4 million in 2023, then surged by 98.93% to $38.5 million in 2024, then soared by 32.51% to $51.0 million in 2025, then surged by 32.24% to $67.5 million in 2026.
• The last three Operating Expenses figures came in at $67.5 million (Q1 2026), $51.0 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.

Peer Comparison